We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $70.90, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.66% loss on the day. At the same time, the Dow lost 0.99%, and the tech-heavy Nasdaq lost 1.63%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 8.93% in the past month. In that same time, the Medical sector lost 9.8%, while the S&P 500 lost 8.1%.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be February 5, 2019. The company is expected to report EPS of $1.65, down 7.3% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.48 billion, down 7.83% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.63 per share and revenue of $21.79 billion. These results would represent year-over-year changes of -25% and -16.52%, respectively.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.61% higher. GILD currently has a Zacks Rank of #2 (Buy).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 10.51. This represents a discount compared to its industry's average Forward P/E of 26.41.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $70.90, marking a +1.66% move from the previous day. This change outpaced the S&P 500's 0.66% loss on the day. At the same time, the Dow lost 0.99%, and the tech-heavy Nasdaq lost 1.63%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 8.93% in the past month. In that same time, the Medical sector lost 9.8%, while the S&P 500 lost 8.1%.
GILD will be looking to display strength as it nears its next earnings release, which is expected to be February 5, 2019. The company is expected to report EPS of $1.65, down 7.3% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.48 billion, down 7.83% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.63 per share and revenue of $21.79 billion. These results would represent year-over-year changes of -25% and -16.52%, respectively.
Any recent changes to analyst estimates for GILD should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.61% higher. GILD currently has a Zacks Rank of #2 (Buy).
Investors should also note GILD's current valuation metrics, including its Forward P/E ratio of 10.51. This represents a discount compared to its industry's average Forward P/E of 26.41.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 85, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.